Asset Publisher

Xabier Buqué García


Electronic mail


Degree in Biochemistry obtained from the Faculty of Science and Technology of the University of the Basque Country, UPV/EHU (2001). Since then I am part of the "Lipids&Liver" Research Group of the Physiology Department of the Faculty of Medicine and Nursing of the University of the Basque Country. In 2007 I obtained my PhD from the UPV/EHU. I have developed my research career, first as contracted research staff and later as teaching and research staff, in the research line directed by Dr. Patricia Aspichueta. In 2014-21 I have a double affiliation as part of the Health Research Institute of Biocruces Bizkaia, attached to the Research Group "Research into the Genetics and Control of Diabetes and other Endocrine Disorders" of the Area of Endocrinology, Metabolism, Nutrition and Renal Diseases.

The main research focus during these years has been to study the mechanisms involved in the development and progression of liver diseases, mainly those related to alterations linked to lipid (fat) metabolism. Our interest is not only to carry out research at a basic level but also to give it a translational character, searching for possible therapeutic targets and early markers of liver disease of metabolic origin. Members since its formation of the National Registry of liver diseases due to metabolic disorders related to fat: Steatosis and non-alcoholic steatohepatitis, HEPAmet dependent on the Spanish Association for the Study of the Liver (AEEH).

I began my teaching career in 2009 as a member of the Biochemistry Teaching Group of the Physiology Department of the Faculty of Medicine and Nursing of the UPV/EHU. In 2021 I passed the competition/opposition in which I occupy the current position as a contract professor. I have taught Medicine Degree at the Faculty of Medicine and Nursing (formerly Dentistry) in the Bachelor's Degree (until 2011) and Degree of Medicine (since 2010). The subjects in which I have taught are: Biochemistry (1st year) and Clinical Biochemistry (3rd year) corresponding to the Bachelor's Degree; and in Degree Basic and Medical Biochemistry (both 1st year), Introduction to Biomedical Research (2nd year) and Research Project (3rd year). Since 2011 I have been teaching in the Master in Biomedical Research and from 2022 in the Master in Molecular Biology and Biomedicine. I have (co)supervised 2 Doctoral Theses of the Clinical Doctorate program; in addition to multiple Final Degree Projects in Medicine, Biotechnology and Biochemistry and Molecular Biology. I have also (co)supervised several Master's Thesis of the Masters in Biomedical Research and Molecular Biology and Biomedicine.

Since 2007 I am part of the Board of the Physiology Department of the FME/EMF and since 2020 I am supervisor of the Radioactive Facility IRA1731 of that Department.


- da Silva Lima N, Fondevila MF, Nóvoa E, Buqué X, et al. “Inhibition of ATG3 ameliorates liver steatosis by increasing mitochondrial function”. J Hepatol. 2021. 21: S0168-8278(21)02038-9. doi: 10.1016/j.jhep.2021.09.008.

- Serrano-Maciá M, Simón J, González-Rellan MJ, Azkargorta M, Goikoetxea-Usandizaga N, Lopitz-Otsoa F, De Urturi DS, Rodríguez-Agudo R, Lachiondo-Ortega S, Mercado-Gomez M, Gutiérrez de Juan V, Bizkarguenaga M, Fernández-Ramos D, Buque X, et al. “Neddylation inhibition ameliorates steatosis in NAFLD by boosting hepatic fatty acid oxidation via the DEPTOR-mTOR axis”. Mol Metab. 2021. 53: 101275. doi: 10.1016/j.molmet.2021.101275.

- González-Romero F, Mestre D, Aurrekoetxea I, O'Rourke CJ, Andersen JB, Woodhoo A, Tamayo-Caro M, Varela-Rey M, Palomo-Irigoyen M, Gómez-Santos B, de Urturi DS, Núñez-García M, García-Rodríguez JL, Fernández-Ares L, Buqué X, et al. “E2F1 and E2F2-Mediated Repression of CPT2 Establishes a Lipid-Rich Tumor-Promoting Environment”. Cancer Res. 2021. 81 (11): 2874-2887. doi: 10.1158/0008-5472.CAN-20-2052.

- Gómez-Santos B, Saenz de Urturi D, Nuñez-García M, Gonzalez-Romero F, Buque X, et al. “Liver osteopontin is required to prevent the progression of age-related nonalcoholic fatty liver disease”. Aging Cell. 2020. 7:e13183. doi: 10.1111/acel.13183.

- Fondevila MF, Fernandez U, Gonzalez-Rellan MJ, Da Silva Lima N, Buque X, et al. “The L-α-lysophosphatidylinositol/GPR55 system induces the development of non-alcoholic steatosis and steatohepatitis”. Hepatology. 2020.

- Simon J, Nuñez-García M, Fernández-Tussy P, Barbier-Torres L, Fernández-Ramos D, Gómez-Santos B, Buqué X, et al. “Targeting Hepatic Glutaminase 1 Ameliorates Non-alcoholic Steatohepatitis by Restoring Very-Low-Density Lipoprotein Triglyceride Assembly”.

Cell Metab. 2020 Mar 3; 31(3): 605-622.e10.

- Fernández Rodríguez CM, Aller R, Gutiérrez García ML, Ampuero J, Gómez-Camarero J, Martín-Mateos RMª, Burgos-Santamaría D, Rosales JM, Aspichueta P, Buque X, et al. “Higher levels of serum uric acid influences hepatic damage in patients with non-alcoholic fatty liver disease (NAFLD)”. Rev Esp Enferm Dig. 2019 Apr; 111(4):264-269.

- Cunarro J, Buque X, et al. “p107 Deficiency Increases Energy Expenditure by Inducing Brown-Fat Thermogenesis and Browning of White Adipose Tissue.”. Mol Nutr Food Res. 2019 Jan; 63(2): e1801096.

- Nuñez-Garcia M, Gomez-Santos B, Saenz de Urturi D, Mestre D, Gonzalez-Romero F, Buque X, et al. “Atorvastatin provides a new lipidome improving early regeneration after partial hepatectomy in osteopontin deficient mice.”. Sci Rep. 2018 Oct 2; 8(1): 14626.

- Porteiro B, Fondevila MF, Buque X, et al. “Pharmacological stimulation of p53 with low-dose doxorubicin ameliorates diet-induced nonalcoholic steatosis and steatohepatitis”. Mol Metab. 2018 Feb;8: 132-143.

- Iruarrizaga-Lejarreta M, Varela-Rey M, Fernández-Ramos D, Martínez-Arranz I, Delgado TC, Simon J, Juan VG, delaCruz-Villar L, Azkargorta M, Lavin JL, Mayo R, Van Liempd SM, Aurrekoetxea I, Buqué X, et al. “Role of Aramchol in steatohepatitis and fibrosis in mice”. Hepatol Commun. 2017 Nov; 1(9):911-927.

- Nuñez-Garcia M, Gomez-Santos B, Buqué X, et al. “Osteopontin regulates the cross-talk between phosphatidylcholine and cholesterol metabolism in mouse liver”. J Lipid Res. 2017 Sep;58(9):1903-1915.

- Martínez-Sánchez N, Seoane-Collazo P, Contreras C, Varela L, Villarroya J, Rial-Pensado E, Buqué X, et al. “Hypothalamic AMPK-ER Stress-JNK1 Axis Mediates the Central Actions of Thyroid Hormones on Energy Balance”. Cell Metab. 2017 Jul 5;26(1):212-229.

- Porteiro B, Fondevila MF, Delgado TC, Iglesias C, Imbernon M, Iruzubieta P, Crespo J, Zabala-Letona A, Fernø J, González-Terán B, Matesanz N, Hernández-Cosido L, Marcos M, Tovar S, Vidal A, Sánchez-Ceinos J, Malagon MM, Pombo C, Zalvide J, Carracedo A, Buque X, et al. “Hepatic p63 regulates steatosis via IKKβ/ER stress”. Nat Commun. 2017 May 8;8:15111.